Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
The transcription factor C/EBPalpha (for CCAAT/enhancer binding protein-alpha; encoded by the gene CEBPA) is crucial for the differentiation of granulocytes. Conditional expression of C/EBPalpha triggers neutrophilic differentiation, and no mature granulocytes are observed in Cebpa-mutant mice. Here we identify heterozygous mutations in CEBPA in ten patients with acute myeloid leukemia (AML). We found that five mutations in the amino terminus truncate the full-length protein, but did not affect a 30-kD protein initiated further downstream. The mutant proteins block wild-type C/EBPalpha DNA binding and transactivation of granulocyte target genes in a dominant-negative manner, and fails to induce granulocytic differentiation. Ours is the first report of CEBPA mutations in human neoplasia, and such mutations are likely to induce the differentiation block found in AML.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We have recently shown mutations in the DNA-binding domain of C/EBP␣ in acute myeloid leukemia, suggesting its importance in granulocyte differentiation and leukemia.19”
From Granulocyte inducer C/EBPα inactivates the myeloid master regulator PU.1: possible role in lineage commitment decisions (2002) · cites this paper as [19]
Citations
Cites
The scanning model for translation: an update.
Kozak, M. (1989) · The Journal of cell biology · doi:10.1083/jcb.108.2.229 · Cited by 3,486 · cited 1×
“These findings support the concept that CEBPA forms detected with monospecific antibodies are alternative products translated from several in-frame initiation codons by a leaky ribosome-scanning mechanis”
BackgroundThe Leucine Zipper: A Hypothetical Structure Common to a New Class of DNA Binding Proteins
Landschulz, W. H., Johnson, P. F., & McKnight, S. L. (1988) · Science · doi:10.1126/science.3289117 · Cited by 3,443
Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells.
Cao, Z., Umek, R. M., & McKnight, S. L. (1991) · Genes & Development · doi:10.1101/gad.5.9.1538 · Cited by 1,663
Chromosomal translocations in human cancer
Rabbitts, T. H. (1994) · Nature · doi:10.1038/372143a0 · Cited by 1,503
Descombes, P., & Schibler, U. (1991) · Cell · doi:10.1016/0092-8674(91)90531-3 · Cited by 990
Isolation of a recombinant copy of the gene encoding C/EBP.
Landschulz, W. H., Johnson, P. F., Adashi, E. Y., Graves, B. J., & McKnight, S. L. (1988) · Genes & Development · doi:10.1101/gad.2.7.786 · Cited by 956
Zhang, D.-E., Zhang, P., Wang, N.-D., Hetherington, C. J., Darlington, G. J., & Tenen, D. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.569 · Cited by 910 · cited 1×
“In addition, no mature granulocytes are observed in Cebpa -mutant mice, whereas all the other blood cell types are present in normal proportion”
BackgroundSelf-citationTranscription Factors, Normal Myeloid Development, and Leukemia
Tenen, D. G., Hromas, R., Licht, J. D., & Zhang, D.-E. (1997) · Blood · doi:10.1182/blood.v90.2.489 · Cited by 735 · cited 1×
“gif" NDATA ITEM> ]> Introduction A number of oncogenes that affect proliferation and cell death have been identified in leukemias and other cancers, but relatively few differentiation genes have been implicated in the malignant phenotyp”
BackgroundSelf-citationCCAAT-Enhancer Binding Protein: A Component of a Differentiation Switch
Umek, R. M., Friedman, A. D., & McKnight, S. L. (1991) · Science · doi:10.1126/science.1987644 · Cited by 712 · cited 1×
“bThe abnormalities were one del(9)(q21), one del(9)(q22q34), one t(6;9), one t(10;21)(p11;q22), one del(7)(q22q34), one +8, one +14, and four complex abnormalities.”
BackgroundRadomska, H. S., Huettner, C. S., Zhang, P., Cheng, T., Scadden, D. T., & Tenen, D. G. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.4301 · Cited by 466 · cited 1×
“cThese patients had a 46,XY,del(12)(p11.”
Self-citation
Cited by
Items 501–600 of 930
Pharmacogenetics of Alkylator-Associated Acute Myeloid Leukemia
Knoche, E., McLeod, H. L., & Graubert, T. A. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.5.719 · Cited by 19
The ASXL1-G643W variant accelerates the development of CEBPA mutant acute myeloid leukemia
D’Altri, T., Wilhelmson, A. S., Schuster, M. B., Wenzel, A., Kalviša, A., Pundhir, S., Hansen, A. M., & Porse, B. T. (2020) · Haematologica · doi:10.3324/haematol.2019.235150 · Cited by 20
The genome-wide molecular signature of transcription factors in leukemia
Prange, K. H. M., Singh, A. A., & Martens, J. H. A. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.04.012 · Cited by 21
Zhang, Y., Peng, L., Hu, T., Wan, Y., Ren, Y., Zhang, J., Wang, X., Zhou, Y., Yuan, W., Wang, Q., et al. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.12.003 · Cited by 20
Szankasi, P., Ho, A. K., Bahler, D. W., Efimova, O., & Kelley, T. W. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.09.018 · Cited by 19
Vries, I. S. N., Sackmann, Y., Klein, F., Ostareck‐Lederer, A., Ostareck, D. H., Jost, E., Ehninger, G., Brümmendorf, T. H., Marx, G., Röllig, C., et al. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.11.007 · Cited by 19
E3 ligase SCFSKP2 ubiquitinates and degrades tumor suppressor C/EBPα in acute myeloid leukemia
Thacker, G., Mishra, M., Sharma, A., Singh, A., Sanyal, S., & Trivedi, A. K. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118041 · Cited by 20
Minetto, P., Candoni, A., Guolo, F., Clavio, M., Zannier, M. E., Miglino, M., Dubbini, M. V., Carminati, E., Sicuranza, A., Ciofini, S., et al. (2020) · Cancers · doi:10.3390/cancers13010034 · Cited by 19
Chen, X., Zhu, H., Qiao, C., Zhao, S., Liu, L., Wang, Y., Jin, H., Qian, S., & Wu, Y. (2021) · Hematology · doi:10.1080/16078454.2020.1858610 · Cited by 25
Rosenberg, A. F., Fan, H., Chiu, Y. G., Bolce, R. J., Tabechian, D., Barrett, R., Moorehead, S., Baribaud, F., Liu, H., Peffer, N. J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110657 · Cited by 19
Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia
Meshinchi, S., Smith, F. O., & Arceci, R. J. (2003) · Current Oncology Reports · doi:10.1007/s11912-003-0010-1 · Cited by 19
Transcribing malignancy: transcription-associated genomic instability in cancer
Boulianne, B., & Feldhahn, N. (2017) · Oncogene · doi:10.1038/onc.2017.402 · Cited by 18
Liss, A. L., Ooi, C.-H., Zjablovskaja, P., Benoukraf, T., Radomska, H. S., Cao, J., Wu, M., Balaštík, M., Delwel, R., Brdička, T., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.093278 · Cited by 21
Self-citationClassification of CEBPA mutated acute myeloid leukemia by GATA2 mutations
Marceau‐Renaut, A., Guihard, S., Castaigné, S., Dombret, H., Preudhomme, C., & Cheok, M. H.-C. (2015) · American Journal of Hematology · doi:10.1002/ajh.23949 · Cited by 18
Wang, H., Chu, T., Han, S., Qi, J., Tang, Y., Qiu, H.-Y., Fu, C., Tang, X., Ruan, C., Wu, D., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.11.031 · Cited by 18
Xu, J., Patrick, B., & Jaiswal, A. K. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.495580 · Cited by 20
FLT3 mutations are associated with other molecular lesions in AML
Carnicer, M. J., Nomdedeu, J. F., Lasa, A., Estivill, C., Brunet, S., n, A. A. X., & Sierra, J. (2003) · Leukemia Research · doi:10.1016/s0145-2126(03)00125-5 · Cited by 18
Marks, J. R., Zawistowski, J. S., Salas-González, I., Tate, T. A., Morozova, T. V., Blackinton, J. G., Arvapalli, D. M., Velivela, S. D., Harton, G., Gawad, C., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.29.489440 · Cited by 19
Ejarque‐Ortiz, A., Tusell, J. M., Serratosa, J., & Saura, J. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21195 · Cited by 17
“In agreement with this, mutations in the CEBPA gene causing a reduced C/EBPa function seem to contribute to some acute myelogenous leukemias (Pabst et al., 2001).”
BackgroundRole of NR4A family members in myeloid cells and leukemia
Boulet, S., Le Corre, L., Odagiu, L., & Labrecque, N. (2022) · Current Research in Immunology · doi:10.1016/j.crimmu.2022.02.001 · Cited by 17
“C/EPB α is a known tumor suppressor mutated in about 10% of AML (Gombart et al., 2002; Pabst et al., 2001) and is a direct target of NR4A1 and NR4A3 (Freire and Conneely, 2018).”
Plummer, R., Sodergren, M. H., Hodgson, R., Ryan, B. M., Raulf, N., Nicholls, J. P., Reebye, V., Voutila, J., Sinigaglia, L., Meyer, T., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102041 · Cited by 19
Fleenor, C. J., Rozhok, A. I., Zaberezhnyy, V., Mathew, D., Kim, J., Tan, A. C., Bernstein, I. D., & DeGregori, J. V. (2015) · Stem Cells · doi:10.1002/stem.1936 · Cited by 17
Khanna‐Gupta, A., Abayasekara, N., Levine, M. S., Sun, H., Virgilio, M., Nia, N., Halene, S., Sportoletti, P., Jeong, J., Pandolfi, P. P., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.373274 · Cited by 18
What Influences the Decision to Proceed to Transplant for Patients With AML in First Remission?
DeWolf, S., Tallman, M. S., Rowe, J. M., & Salman, M. Y. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02868 · Cited by 18
Diabetes Inhibits Gr-1+ Myeloid Cell Maturation via Cebpa Deregulation
Wicks, K., Torbica, T., Umehara, T., Amin, S., Bobola, N., & Mace, K. A. (2015) · Diabetes · doi:10.2337/db14-1895 · Cited by 19
Mans, S., Banz, Y., Mueller, B. U., & Pabst, T. (2012) · Blood · doi:10.1182/blood-2012-02-412759 · Cited by 17
“Lineage specific transcription factors such as CCAAT/enhancer binding protein-alpha (CEBPA) are crucial for normal neutrophil maturation, and they are obvious targets for disruption in AML [1-3].”
BackgroundSelf-citationC/EBPα mutations in lung cancer
Costa, D. B., Dayaram, T., D’Alò, F., Wouters, B. J., Tenen, D. G., Meyerson, M. M., Tsao, M., & Halmos, B. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.04.011 · Cited by 17
Self-citationFunctional Polymorphism of the Anpep Gene Increases Promoter Activity in the Dahl Salt-Resistant Rat
Kumar, K. U., Hughes, D. E., Herrera, V. L. M., Ruiz‐Opazo, N., Costa, R. H., Robey, R. B., & Danziger, R. S. (2007) · Hypertension · doi:10.1161/01.hyp.0000256303.40359.38 · Cited by 17
Zhou, T., Wang, L., Zhu, K.-Y., Dong, M., Xu, P., Chen, Y., Chen, S., Zhu, C. H., Deng, M., & Liu, T. X. (2011) · Blood · doi:10.1182/blood-2010-12-327908 · Cited by 17
Pabst, T., Stillner, E., Neuberg, D. S., Nimer, S. D., Willman, C. L., List, A. F., Melo, J. V., Tenen, D. G., & Mueller, B. U. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06057.x · Cited by 17
Self-citationInherited Predispositions to Myeloid Neoplasms: Pathogenesis and Clinical Implications
Liu, Y.-C., Eldomery, M. K., Maciaszek, J. L., & Klco, J. M. (2025) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-111523-023420 · Cited by 16
Wang, D., Sun, T., Xia, Y., Zhao, Z., Sheng, X., Li, S., Ma, Y., Li, M., Su, X., Zhang, F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42650-3 · Cited by 18
Molecular Genetic Biomarkers in Myeloid Malignancies
Matynia, A. P., Szankasi, P., Shen, W., & Kelley, T. W. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0096-ra · Cited by 17
Molecular and Clinicopathologic Characterization of AML With Isolated Trisomy 4
Bains, A., Lu, G. G., Yao, H., Luthra, R., Medeiros, L. J., & Sargent, R. L. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcp7zc9yqerskgx · Cited by 16
Heiblig, M., Labussière‐Wallet, H., Nicolini, F. E., Michallet, M., Hayette, S., Sujobert, P., Pleșa, A., Balsat, M., Paubelle, É., Barraco, F., et al. (2019) · Cancers · doi:10.3390/cancers11040570 · Cited by 16
Simone, L., Pisani, F., Binda, E., Frigeri, A., Vescovi, A. L., Svelto, M., & Nicchia, G. P. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00888-2 · Cited by 17
Fuster, Ó., Barragán, E., Bolufer, P., Such, E., Valencia, A., Ibáñez, M., Dolz, S., de Juan, I., Jiménez, A., Gómez‐Casares, M. T., et al. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1234-z · Cited by 16
“The lower detection limit of the method described here (5% for TAD1, 1% for TAD2, and 2% for BZIP mutations) is even lower than that of nucleotide sequencing (20%), which is the most commonly used method for CEBPA mutation detection [9, 20].”
BackgroundMethodArber, D. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-47913-4.00014-8 · Cited by 16
Multiple ways of C/EBPα inhibition in myeloid leukaemia
Trivedi, A. K., Pal, P., Behre, G., & Singh, S. M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.04.022 · Cited by 16
Self-citationPredicting the effect of transcription therapy in hematologic malignancies
Melnick, A. M. (2005) · Leukemia · doi:10.1038/sj.leu.2403777 · Cited by 17
Genetic Changes of CEBPA in Cancer: Mutations or Polymorphisms?
Resende, C., Regalo, G., Durães, C., Carneiro, F., & Machado, J. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.7227 · Cited by 19
Loss of C/EBPα and Favorable Prognosis of Acute Myeloid Leukemias: A Biological Paradox
Perrotti, D., Marcucci, G., & Caligiuri, M. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.965 · Cited by 18
“[11,12].”
BackgroundInteractive diagnostics in the indication to allogeneic SCT in AML
Bacher, U., Haferlach, C., Schnittger, S., Kern, W., Kröger, N., Zander, A. R., & Haferlach, T. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.54 · Cited by 15
Self-citationNiebuhr, B., Iwanski, G. B., Schwieger, M., Roscher, S., Stocking, C., & Cammenga, J. (2008) · Leukemia · doi:10.1038/leu.2008.332 · Cited by 17
Xu, J., & Jaiswal, A. K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.387738 · Cited by 15
RetractedYin, H., Smith, M., & Glass, J. (2004) · The Prostate · doi:10.1002/pros.20136 · Cited by 15
Oveland, E., Gjertsen, B. T., Wergeland, L., Selheim, F., Fladmark, K. E., & Hovland, R. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.06.029 · Cited by 15
Gou, H., Zhou, J., Ye, Y., Hu, X. L., Shang, M., Zhang, J., Zhao, Z., Peng, W., Zhou, Y., Zhou, Y., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-4601-x · Cited by 15
“[37]”
Kansal, R. (2019) · Human Pathology · doi:10.1016/j.humpath.2019.04.020 · Cited by 15
Gianfaldoni, G., Mannelli, F., Intermesoli, T., Bencini, S., Giupponi, D., Farina, G., Cutini, I., Bonetti, M. I., Masciulli, A., Audisio, E., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000406 · Cited by 15
CDK2-instigates C/EBPα degradation through SKP2 in Acute myeloid leukemia
Thacker, G., Mishra, M., Sharma, A., Singh, A., Sanyal, S., & Trivedi, A. K. (2021) · Medical Oncology · doi:10.1007/s12032-021-01523-9 · Cited by 15
Hankey, W., Silver, M., Sun, H., Zibello, T., Berliner, N., & Khanna‐Gupta, A. (2011) · Hematology Reports · doi:10.4081/hr.2011.e5 · Cited by 16
Hirai, H. (2002) · International Journal of Hematology · doi:10.1007/bf03165120 · Cited by 21
Behre, G., Reddy, V. A., Tenen, D. G., Hiddemann, W., Zada, A. A. P., & Singh, S. M. (2002) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.6.4.491 · Cited by 15
Self-citationChen, S., Yan, X., Zhou, G., & Chen, Z. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm011 · Cited by 15
Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome
Arai, H., Matsui, H., Chi, S., Utsu, Y., Masuda, S., Aotsuka, N., & Minami, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010652 · Cited by 14
“The prognosis of CEBPA -associated familial AML appears to be better than that of sporadic CEBPA -associated AML [114,115].”
BackgroundGeest, C. R., Buitenhuis, M., Vellenga, E., & Coffer, P. J. (2009) · Haematologica · doi:10.3324/haematol.2008.000471 · Cited by 14
Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia
Büchner, T., Krug, U. O., Gale, R. P., Heinecke, A., Sauerland, M. C., Haferlach, C., Schnittger, S., Haferlach, T., Müller‐Tidow, C., Stelljes, M., et al. (2016) · Leukemia · doi:10.1038/leu.2016.54 · Cited by 14
Self-citationGenetic profiling in acute myeloid leukemia: a path to predicting treatment outcome
Visani, G., Loscocco, F., Isidori, A., & Piccaluga, P. P. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1475225 · Cited by 14
Zanotto, E., Häkkinen, A., Teku, G., Shen, B., Ribeiro, A. S., & Jacobs, H. T. (2009) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2009.05.001 · Cited by 14
Oncogènes et leucémies : historique et perspectives
Gisselbrecht, S. (2003) · médecine/sciences · doi:10.1051/medsci/2003192201 · Cited by 17
Familial Acute Myeloid Leukemia and Myelodysplasia in Hungary
Király, A. P., Kállay, K. M., Gángó, A., Kellner, Á., Egyed, M., Szőke, A., Kiss, R., Valyi-Nagy, I. T., Csomor, J., Matolcsy, A., et al. (2017) · Pathology & Oncology Research · doi:10.1007/s12253-017-0216-4 · Cited by 15
Functional roles of C/EBPα and SUMO-modification in lung development
Chen, Y.-D., Liu, J., Lu, Y., Zhu, H., Tang, W., Wang, Q., & Lu, H. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3111 · Cited by 14
Mizushima, Y., Taki, T., Shimada, A., Yui, Y., Hiraumi, Y., Matsubara, H., Watanabe, M., Watanabe, K.-I., Kamitsuji, Y., Hayashi, Y., et al. (2010) · International Journal of Hematology · doi:10.1007/s12185-010-0585-x · Cited by 14
Bret, C., Viziteu, E., Kassambara, A., & Moreaux, J. (2016) · Expert Review of Hematology · doi:10.1586/17474086.2016.1141673 · Cited by 15
Qian, J., Chen, Z., Lin, J., Wang, W., & Cen, J. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.05.020 · Cited by 16
Zhang, J., Wilkinson, J. E., Gonit, M., Keck, R. W., Selman, S. H., & Ratnam, M. (2008) · The Prostate · doi:10.1002/pros.20779 · Cited by 13
Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations
Ji, Y., He, R., & Alkhateeb, H. B. (2023) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-023-00699-3 · Cited by 13
Westergaard, D., Jørgensen, F. H., Waaben, J., Jung, A. W., Lademann, M., Hansen, T. F., Cremers, J., Ostrowski, S. R., Pedersen, O. B., Reguant, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51795-8 · Cited by 15
Wertheim, G. B. W., & Bagg, A. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.11.19 · Cited by 15
Derangement of transcription factor profiles during in vitro differentiation of HL60 and NB4 cells
Bjerregaard, M. D., Borregaard, N., & Cowland, J. B. (2006) · Leukemia Research · doi:10.1016/j.leukres.2006.07.019 · Cited by 17
The role of aberrant transcription factor in the progression of chronic myeloid leukemia
Zhang, S. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802163305 · Cited by 15
Recent progress on targeting leukemia stem cells
Ma, X., Wei, L., Lei, Z., Chen, Y., Ding, Z., & Chen, Z. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.05.009 · Cited by 13
Thomadaki, H., Floros, K. V., Pavlović, S., Tos̆ić, N., Gourgiotis, D., Čolović, M., & Scorilas, A. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.06.012 · Cited by 13
Sarojam, S., Raveendran, S. K., Vijay, S., Sreedharan, J., Narayanan, G., & Sreedharan, H. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.9.3785 · Cited by 13
“CEBPA mutation was detected in 8%-19% of NK-AML (Pabst et al., 2001; Gombart et al., 2002; Dufour et al., 2010).”
BackgroundInfluentialSleadd, I. M., & Buckley, B. A. (2012) · Polar Biology · doi:10.1007/s00300-012-1262-8 · Cited by 14
“…including adipocyte differentiation, hematopoiesis, liver regeneration, memory consolidation, inflammation, and cancer (Darlington et al. 1998; Diehl 1998; Lekstrom-Himes and Xanthopolous 1998; Poli 1998; Lane et al. 1999; Pabst et al. 2001; Ramji and Foka 2002; Nerlov 2007; Moore et al. 2012).”
BackgroundImportant features of myelodysplastic syndrome
Hofmann, W., & Koeffler, H. P. (2002) · International Journal of Hematology · doi:10.1007/bf03165121 · Cited by 15
Moreau-Gachelin, F. (2006) · PubMed · Cited by 18
Fleenor, C. J., Higa, K. C., Weil, M. M., & DeGregori, J. V. (2015) · Radiation Research · doi:10.1667/rr14147.1 · Cited by 13
The Role of Translation Initiation Regulation in Haematopoiesis
Grech, G., & Lindern, M. V. (2012) · Comparative and Functional Genomics · doi:10.1155/2012/576540 · Cited by 13
“The role of eIF4E phosphorylation is still controversial.”
BackgroundPathology Consultation on Gene Mutations in Acute Myeloid Leukemia
Ziai, J. M., & Siddon, A. J. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcp77zfpuqgygwy · Cited by 13
Zhao, B., Zhang, Z., Chen, X., Shen, Y., Qin, Y., Yang, X., Xing, Z., Zhang, S., Long, X., Zhang, Y., et al. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30143 · Cited by 12
“C/EBPα binds to the promoters of many myeloid‐specific genes and regulates their transcriptional activity at different stages of myeloid maturation (Pabst et al., 2001).”
BackgroundKok, V. C., Wang, C. C. N., Liao, S.-H., & Chen, D.-L. (2022) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s359346 · Cited by 12
G ENETIC P ROFILE OF A CUTE M YELOID L EUKEMIA
Mecucci, C., Rosati, R., & Starza, R. L. (2002) · Reviews in Clinical and Experimental Hematology · doi:10.1046/j.1468-0734.2002.00060.x · Cited by 13
Signaling revisited in acute promyelocytic leukemia
Lutz, P. G., Moog‐Lutz, C., & Cayre, Y. (2002) · Leukemia · doi:10.1038/sj.leu.2402728 · Cited by 12
Mendoza, H., Podoltsev, N. A., & Siddon, A. J. (2021) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13517 · Cited by 12
Prognostically Important Molecular Markers in Cytogenetically Normal Acute Myeloid Leukemia
Lin, T. L., Smith, B. D., & Lopez, F. A. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e318201109d · Cited by 12
Bai, Y., Chen, C. Y., Guo, X., Ding, T., Yang, X., Yu, J. C., Yang, J., Ruan, J., Zheng, X., & Chen, Z. (2020) · Cancer Biomarkers · doi:10.3233/cbm-190899 · Cited by 11
Largeaud, L., Cornillet‐Lefèbvre, P., Hamel, J., Dumas, P., Prade, N., Dufrechou, S., Plenecassagnes, J., Luquet, I., Blanchet, O., Banos, A., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01031-1 · Cited by 13
Symeonidis, A. S., Chatzilygeroudi, T., Chondrou, V., & Sgourou, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416069 · Cited by 11
Absence of somatic mutations within the Runt domain of AML2/RUNX3 in acute myeloid leukaemia
Otto, F., Stock, M., Fliegauf, M., Fenaux, P., Preudhomme, C., & Lübbert, M. (2003) · Leukemia · doi:10.1038/sj.leu.2403007 · Cited by 11
Togami, K., Kitaura, J., Uchida, T., Inoue, D., Nishimura, K., Kawabata, K. C., Nagase, R., Horikawa, S., Izawa, K., Fukuyama, T., et al. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.11.011 · Cited by 14
Ko, Y.-C., Fang, W.-H., Lin, T.-C., Hou, H., Chen, C., Tien, H., & Lin, L. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.03.008 · Cited by 11
Häkkinen, A., Healy, S., Jacobs, H. T., & Ribeiro, A. S. (2011) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2011.04.027 · Cited by 11
“Defects or malfunctioning of these CCAAT boxes have been linked to several diseases, including some forms of cancer (Farina et al., 1999; Pabst et al., 2001).”
BackgroundMarcolin, R., Guolo, F., Minetto, P., Clavio, M., Manconi, L., Ballerini, F., Carli, A., Passannante, M., Colombo, N., Carminati, E., et al. (2019) · Leukemia Research · doi:10.1016/j.leukres.2019.106223 · Cited by 11
Ferrari‐Amorotti, G., Mariani, S. A., Novi, C., Cattelani, S., Pecorari, L., Corradini, F., Soliera, A. R., Manzotti, G., Fragliasso, V., Zhang, Y., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.128272 · Cited by 15
Wen, C.-L., Teng, C. J., Chiang, C., Chang, C.-C., Hwang, W.-L., Kuo, C., & Hsu, S. (2012) · Phytomedicine · doi:10.1016/j.phymed.2011.11.003 · Cited by 12
“…of C/EBP family of transcription factors, C/EBP and C/EBP are known to be critical for normal granulocytic differentiation (Gery et al. 2005; Pabst et al. 2001; Porse et al. 2005; Tenen et al. 1997), while C/EBP is particularly important for macrophage function (Lekstrom-Himes and…”
BackgroundRapino, F. A., Robles, E. F., Richter-Larrea, J. A., Kallin, E. M., Martinez-Climent, J. A., & Graf, T. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.072 · Cited by 11
Wang, L., Xiao, H., Zhang, X., LIAO, W., Fu, S., & Huang, H. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3163 · Cited by 11
Transcription factors in hematopoietic malignancies
Gery, S., & Koeffler, H. P. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.012 · Cited by 11
Metadata
- Authors
- Pabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., & Tenen, D. G.
- Affiliations
- Harvard University (US)
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Tenen, Daniel G.
- Venue
- Nature Genetics
- Published
- 2001-03
- Volume
- 27
- Issue
- 3
- Pages
- 263-270
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2100088478
- Cited by
- 901
- References
- 33
- Citations by year
- 2026: 15 · 2025: 11 · 2024: 23 · 2023: 21 · 2022: 30 · 2021: 22 · 2020: 27 · 2019: 17 · 2018: 22 · 2017: 27 · 2016: 29 · 2015: 47 · 2014: 37 · 2013: 34 · 2012: 50
- FWCI
- 23.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL056745, HL56745)
- National Cancer Institute (CA-72009, P01CA072009)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Blood disorders and treatments
- Keywords
- CEBPA, C/EBPα, acute myeloid leukemia, dominant negative mutation, heterozygous mutation, transcription factors, granulocytic differentiation, DNA binding, transcriptional activation, N-terminal truncation
- MeSH terms
- Base Sequence, Cell Differentiation, Cell Nucleus, DNA, Neoplasm, Genes, Dominant, Granulocytes, Heterozygote, Humans, Mutation, Neutrophils, Leukemia, Myeloid, Acute, Transcriptional Activation, Sequence Deletion, DNA Primers, CCAAT-Enhancer-Binding Protein-alpha, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.